In CheckMate 214, International Metastatic RCC Database Consortium (IMDC) intermediate/poor-risk ccRCC patients treated with nivolumab plus ipilimumab (anti-CTLA-4) had significant benefit in OS, PFS, quality of life, and subsequent treatment-free survival compared to those treated with sunitinib [24,25]. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.